Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Arcadia Biosciences (RKDA) EBT (2016 - 2025)

Arcadia Biosciences filings provide 12 years of EBT readings, the most recent being $634000.0 for Q4 2025.

  • On a quarterly basis, EBT rose 115.74% to $634000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$489000.0, a 90.12% increase, with the full-year FY2025 number at -$2.3 million, up 45.9% from a year prior.
  • EBT hit $634000.0 in Q4 2025 for Arcadia Biosciences, up from -$1.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $5.6 million in Q4 2021 to a low of -$5.4 million in Q2 2021.
  • Median EBT over the past 5 years was -$1.4 million (2024), compared with a mean of -$1.5 million.
  • Biggest five-year swings in EBT: soared 183.12% in 2023 and later plummeted 805.39% in 2024.
  • Arcadia Biosciences' EBT stood at $5.6 million in 2021, then plummeted by 156.62% to -$3.2 million in 2022, then soared by 85.95% to -$445000.0 in 2023, then plummeted by 805.39% to -$4.0 million in 2024, then surged by 115.74% to $634000.0 in 2025.
  • The last three reported values for EBT were $634000.0 (Q4 2025), -$1.2 million (Q3 2025), and -$501000.0 (Q2 2025) per Business Quant data.